Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.46 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | CTSB | P07858 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870379 | 1.00 | CTSS (0.46) | CTSSCTSKCTSBPKMSMN1; SMN2 | |
| SCHEMBL3873938 | 0.95 | CTSS (0.49) | CTSSCTSKCTSBPKMSMN1; SMN2 | |
| SCHEMBL3873937 | 0.95 | CTSS (0.49) | CTSSCTSKCTSBPKMSMN1; SMN2 | |
| SCHEMBL13758655 | 0.91 | CTSS (0.46) | CTSSCTSKCTSBPKMSMN1; SMN2 | |
| SCHEMBL8291546 | 0.89 | CTSS (0.36) | CTSSCTSKCTSBPKMSMN1; SMN2 | |
| SCHEMBL3872654 | 0.89 | CTSS (0.47) | CTSSCTSKCTSBPKMSMN1; SMN2 | |
| SCHEMBL8292302 | 0.86 | CTSS (0.59) | CTSSCTSKCTSBCAPN1 | |
| SCHEMBL8289950 | 0.85 | CTSS (0.49) | CTSSCTSKCTSBPKMSMN1; SMN2 | |
| SCHEMBL3873469 | 0.85 | PKM (0.49) | CTSSCTSKCTSBPKMSMN1; SMN2 | |
| SCHEMBL3871054 | 0.83 | CTSS (0.50) | CTSSCTSKCTSBPKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482448-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-1682524-A1 | NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005040142-A1 | NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSB, CTSS, CTSK | CTSS 2/4885CTSK 3/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.